Federal Circuit Rules Against Teva, Redefines Criteria for Orange Book Patent Listings

In a recent ruling, the Federal Circuit has upheld a decision against Teva Pharmaceuticals regarding their listing of asthma inhaler patents in the U.S. Food and Drug Administration’s Orange Book. This ruling clarifies that only patents directly claiming a drug’s active ingredient are eligible for inclusion in this critical database, which plays a significant role in regulating drug approvals and exclusivity periods. Legal professionals and pharmaceutical companies might want to examine the implications of this decision on future patent filings and the strategic management of drug patent portfolios. For more detailed information, refer to the original Law360 article.